Acute toxicity and antitumor potential of 1,3,4‐trisubstituted‐1,2,3‐triazole dhmtAc‐loaded liposomes on a triple‐negative breast cancer model

For the first time, compounds developed from the 1,2,3‐triazole scaffold were evaluated as novel drugs to treat triple‐negative breast cancer (TNBC). Four organic salts were idealized as nonclassical bioisosteres of miltefosine, which is used in the topical treatment for skin metastasizing breast ca...

Full description

Saved in:
Bibliographic Details
Published in:Archiv der Pharmazie (Weinheim) 2022-09, Vol.355 (9), p.e2200004-n/a
Main Authors: Ramos, Jonas P., Abdel‐Salam, Mostafa A. L., Nobre, Daniel A. B., Glanzmann, Nicolas, de Souza, Camila P., Leite, Elaine A., de Abreu Teles, Pedro P., Barbosa, Alan S., Barcelos, Luciola S., dos Reis, Diego C., Cassali, Geovanni D., de Lima, Maria E., de Castro, Quênia J. T., Grabe‐Guimarães, Andrea, da Silva, Adilson D., de Souza‐Fagundes, Elaine M.
Format: Article
Language:English
Subjects:
1,2,3‐triazoles
3‐triazoles
Breast cancer
miltefosine
pH‐sensitive liposome
TNBC
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:For the first time, compounds developed from the 1,2,3‐triazole scaffold were evaluated as novel drugs to treat triple‐negative breast cancer (TNBC). Four organic salts were idealized as nonclassical bioisosteres of miltefosine, which is used in the topical treatment for skin metastasizing breast carcinoma. Among them, derivative dhmtAc displayed better solubility and higher cytotoxicity against the human breast adenocarcinoma cell line and mouse 4T1 cell lines, which are representatives of TNBC. In vitro assays revealed that dhmtAc interferes with cell integrity, confirmed by lactate dehydogenase leakage. Due to its human peripheral blood mononuclear cell (PBMC) toxicity, dhmtAc in vivo studies were carried out with the drug incorporated in a long‐circulating and pH‐sensitive liposome (SpHL‐dhmtAc), and the acute toxicity in BALB/c mice was determined. Free dhmtAc displayed cardiac and pulmonary toxicity after the systemic administration of 5 mg/kg doses. On the other hand, SpHL‐dhmtAc displayed no toxicity at 20 mg/kg. The in vivo antitumor effect of SpHL‐dhmtAc was investigated using the 4T1 heterotopic murine model. Intravenous administration of SpHL‐dhmtAc reduced the tumor volume and weight, without interfering with the body weight, compared with the control group and the dhmtAc free form. The incorporation of the triazole compound in the liposome allowed the demonstration of its anticancer potential. These findings evidenced 1,3,4‐trisubstituted‐1,2,3‐triazole as a promising scaffold for the development of novel drugs with applicability for the treatment of patients with TNBC. Compounds developed from the 1,2,3‐triazole scaffold were evaluated as novel drugs to treat triple‐negative breast cancer (TNBC). Four organic salts were idealized as nonclassical bioisosteres of miltefosine. Among them, derivative dhmtAc displayed better solubility and higher cytotoxicity against the human MDA‐MB‐231 and mouse 4T1 cell lines, which are representatives of TNBC. dhmtAc incorporated in a long‐circulating, pH‐sensitive liposome (SpHL‐dhmtAc) shows reduced toxicity.
ISSN:0365-6233
1521-4184
DOI:10.1002/ardp.202200004